MBHB Associate Taylor Weilnau Discusses Potential Outcomes of Supreme Court “Skinny Labeling” Case in Law360

In Law360, MBHB Associate Taylor Weilnau shares her analysis of the potential outcomes that could result from the U.S. Supreme Court’s review of the Hikma v. Amarin case and the implications for both generic and brand-name drugmakers. Read more here.